Cofco Biotechnology (000930.SZ) released its forecasted profit, expecting a net profit of 18-27 million yuan in 2024, turning losses into profits compared to the previous year.
COFCO Technology & Industry Co., Ltd. (000930.SZ) released the annual performance forecast for 2024, expecting a full-year net profit attributable to shareholders of the listed company...
Cofco Biotechnology (000930.SZ) announced its annual performance forecast for 2024, expecting a net profit attributable to shareholders of the listed company of 18-27 million yuan, turning losses into profits compared to the previous year.
In 2024, the company closely monitors market changes, adjusts procurement and sales pace in a timely manner, utilizes "spot-futures integration" to control operational risks, continuously promotes low-cost systems and intensifies efforts to reduce consumption, leading to steady progress in operations.
Related Articles
HK Stock Market Move | Innovative drug concept stocks retreated. InnoCare Pharma (09969) fell over 8%, REMEGEN (09995) dropped nearly 6%.
Goldman Sachs: Macau September gaming revenue down 1% year-on-year, in line with expectations; expects stable third-quarter EBITDA
HK Stock Market Move | BOYAA (00434) rises over 4%; Bitcoin briefly breaks above $86,000; Citi sees target price as high as $113,000.
HK Stock Market Move | Innovative drug concept stocks retreated. InnoCare Pharma (09969) fell over 8%, REMEGEN (09995) dropped nearly 6%.
Goldman Sachs: Macau September gaming revenue down 1% year-on-year, in line with expectations; expects stable third-quarter EBITDA
HK Stock Market Move | BOYAA (00434) rises over 4%; Bitcoin briefly breaks above $86,000; Citi sees target price as high as $113,000.
